Gu Si-Lan, Chen Yun-Bo, Lv Tao, Zhang Xue-Wu, Wei Ze-Qing, Shen Ping, Li Lan-Juan
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR China.
Hematology Department, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China.
J Med Microbiol. 2015 Mar;64(Pt 3):209-216. doi: 10.1099/jmm.0.000028. Epub 2015 Jan 16.
The purpose of this study was to evaluate the risk factors, outcomes and epidemiology associated with Clostridium difficile infection (CDI) in patients with haematological malignancies in a tertiary care hospital in China. C. difficile screening was performed on patients admitted for chemotherapy or haematopoietic stem cell transplantation between 2009 and 2013. C. difficile isolates were analysed by multilocus sequence typing, and a retrospective chart review was performed on all patients with a positive toxin assay. CDI was diagnosed in 21 haematology-oncology ward patients and 14 marrow transplantation service patients for a cumulative incidence of 1.89/1000 and 3.69/1000 patient-days, respectively. Univariate analyses showed that patients who received etoposide had an increased risk of CDI (odds ratio 4.25, 95 % confidence interval 1.32-13.64). There was only one patient death, for which CDI was not the primary cause. Ten sequence types (STs) were identified, of which ST-3 and ST-54 were the most common; the hypervirulent ST-1 (ribotype 027) and ST-11 (ribotype 078) C. difficile strains were not detected in the patients in this study. The incidence of CDI did not differ between patients receiving chemotherapy and those receiving haematopoietic stem cell transplantation. The only risk factor for chemotherapy patients was treatment with etoposide.
本研究旨在评估中国一家三级医院血液系统恶性肿瘤患者艰难梭菌感染(CDI)的危险因素、结局及流行病学情况。对2009年至2013年间因化疗或造血干细胞移植入院的患者进行艰难梭菌筛查。对艰难梭菌分离株进行多位点序列分型分析,并对所有毒素检测呈阳性的患者进行回顾性病历审查。血液肿瘤病房21例患者及骨髓移植科14例患者诊断为CDI,累积发病率分别为1.89/1000和3.69/1000患者日。单因素分析显示,接受依托泊苷治疗的患者发生CDI的风险增加(比值比4.25,95%置信区间1.32 - 13.64)。仅有1例患者死亡,CDI并非主要死因。共鉴定出10种序列类型(STs),其中ST-3和ST-54最为常见;本研究患者中未检测到高毒力的ST-1(核糖体分型027)和ST-11(核糖体分型078)艰难梭菌菌株。接受化疗的患者与接受造血干细胞移植的患者之间CDI发病率无差异。化疗患者唯一的危险因素是接受依托泊苷治疗。